Literature DB >> 34448873

T-Cell Immune Dysregulation and Mortality in Women With Human Immunodeficiency Virus.

Brandilyn A Peters1, Jee-Young Moon1, David B Hanna1, Olaf Kutsch2, Margaret Fischl3, Caitlin A Moran4, Adaora A Adimora5, Stephen Gange6, Nadia R Roan7, Katherine G Michel8, Michael Augenbraun9, Anjali Sharma10, Alan Landay11, Seema Desai11, Robert C Kaplan1,12.   

Abstract

SUMMARY: In women with HIV, higher activation and exhaustion of CD4+ T cells were associated with risk of non-HIV-related mortality during a median of 13.3 years of follow-up, independent of baseline demographic, behavioral, HIV-related, and cardiometabolic factors and longitudinal HIV disease progression.
BACKGROUND: Dysregulation of adaptive immunity is a hallmark of human immunodeficiency virus (HIV) infection that persists on antiretroviral therapy (ART). Few long-term prospective studies have related adaptive immunity impairments to mortality in HIV, particularly in women.
METHODS: Among 606 women with HIV in the Women's Interagency HIV Study, peripheral blood mononuclear cells collected from 2002 to 2005 underwent multiparameter flow cytometry. Underlying cause of death was ascertained from the National Death Index up to 2018. We examined associations of CD4+ and CD8+ T-cell activation (%CD38+HLA-DR+), senescence (%CD57+CD28-), exhaustion (%PD-1+), and nonactivation/normal function (%CD57-CD28+) with natural-cause, HIV-related, and non-HIV-related mortality.
RESULTS: At baseline, median participant age was 41, and 67% were on ART. Among 100 deaths during a median of 13.3 years follow-up, 90 were natural-cause (53 non-HIV-related, 37 HIV-related). Higher activation and exhaustion of CD4+ T cells were associated with risk of natural-cause and non-HIV-related mortality, adjusting for age, demographic, behavioral, HIV-related, and cardiometabolic factors at baseline. Additional adjustment for time-varying viral load and CD4+ T-cell count did not attenuate these associations. CD8+ T-cell markers were not associated with any outcomes adjusting for baseline factors.
CONCLUSIONS: Persistent CD4+ T-cell activation and exhaustion may contribute to excess long-term mortality risk in women with HIV, independent of HIV disease progression.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; T-cell; immune activation; mortality

Mesh:

Substances:

Year:  2022        PMID: 34448873      PMCID: PMC8844590          DOI: 10.1093/infdis/jiab433

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  41 in total

1.  HIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis.

Authors:  David B Hanna; Wendy S Post; Jennifer A Deal; Howard N Hodis; Lisa P Jacobson; Wendy J Mack; Kathryn Anastos; Stephen J Gange; Alan L Landay; Jason M Lazar; Frank J Palella; Phyllis C Tien; Mallory D Witt; Xiaonan Xue; Mary A Young; Robert C Kaplan; Lawrence A Kingsley
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

2.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.

Authors:  Peter W Hunt; Elizabeth Sinclair; Benigno Rodriguez; Carey Shive; Brian Clagett; Nicholas Funderburg; Janet Robinson; Yong Huang; Lorrie Epling; Jeffrey N Martin; Steven G Deeks; Curtis L Meinert; Mark L Van Natta; Douglas A Jabs; Michael M Lederman
Journal:  J Infect Dis       Date:  2014-04-21       Impact factor: 5.226

3.  The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.

Authors:  Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

Review 4.  Immune activation and HIV persistence: considerations for novel therapeutic interventions.

Authors:  Hiroyu Hatano
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

5.  Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.

Authors:  Virginia A Triant; Hang Lee; Colleen Hadigan; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2007-04-24       Impact factor: 5.958

6.  Cohort Profile: The Women's Interagency HIV Study (WIHS).

Authors:  Adaora A Adimora; Catalina Ramirez; Lorie Benning; Ruth M Greenblatt; Mirjam-Colette Kempf; Phyllis C Tien; Seble G Kassaye; Kathryn Anastos; Mardge Cohen; Howard Minkoff; Gina Wingood; Igho Ofotokun; Margaret A Fischl; Stephen Gange
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

7.  Sex- and Poverty-Specific Patterns in Cardiovascular Disease Mortality Associated With Human Immunodeficiency Virus, New York City, 2007-2017.

Authors:  David B Hanna; Chitra Ramaswamy; Robert C Kaplan; Jorge R Kizer; Demetre Daskalakis; Kathryn Anastos; Sarah L Braunstein
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 20.999

8.  Modulation of HIV replication in monocyte derived macrophages (MDM) by steroid hormones.

Authors:  Krishnakumar Devadas; Santanu Biswas; Viswanath Ragupathy; Sherwin Lee; Andrew Dayton; Indira Hewlett
Journal:  PLoS One       Date:  2018-01-26       Impact factor: 3.240

Review 9.  T-cell exhaustion in HIV infection.

Authors:  Craig Fenwick; Victor Joo; Patricia Jacquier; Alessandra Noto; Riddhima Banga; Matthieu Perreau; Giuseppe Pantaleo
Journal:  Immunol Rev       Date:  2019-11       Impact factor: 12.988

10.  CD28 and CD57 define four populations with distinct phenotypic properties within human CD8+ T cells.

Authors:  Luca Pangrazzi; Jürgen Reidla; José Antonio Carmona Arana; Erin Naismith; Carina Miggitsch; Andreas Meryk; Michael Keller; Adelheid Alma Nora Krause; Franz Leonard Melzer; Klemens Trieb; Michael Schirmer; Beatrix Grubeck-Loebenstein; Birgit Weinberger
Journal:  Eur J Immunol       Date:  2019-12-04       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.